Cabaletta Bio (CABA) announced the appointment of Steve Gavel as Chief Commercial Officer, CCO, effective immediately. In his role, Gavel will join the leadership team and will lead all aspects of global commercial strategy and execution for rese-cel for which the Company anticipates its first Biologics License Application, BLA, submission in myositis in 2027, as well as potential future pipeline opportunities.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CABA:
- 3 Best Stocks to Buy Now, 10/10/2025, According to Top Analysts
- Promising Potential of Cabaletta Bio’s Rese-cel Therapy Drives Buy Rating
- Promising Early Data from Cabaletta Bio’s Rese-cel Therapy Suggests Significant Potential in Autoimmune Treatment
- Cabaletta Bio jumps 30% to $3.13 after pemphigus vulgaris data
- Cabaletta Bio Presents Promising RESET-PV Trial Data